Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
about
Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis.DNAVaxDB: the first web-based DNA vaccine database and its data analysis.FDA guidance on prophylactic DNA vaccines: analysis and recommendations.Generation of transgenic pigs by cytoplasmic injection of piggyBac transposase-based pmGENIE-3 plasmids.Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yieldsDevelopment of Streptococcus pneumoniae Vaccines Using Live VectorsLow-dose plasmid DNA treatment increases plasma vasopressin and regulates blood pressure in experimental endotoxemia.Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes.Mechanisms of tolerance and high degradation capacity of the herbicide mesotrione by Escherichia coli strain DH5-α.Technologies for enhanced efficacy of DNA vaccines.Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.Large-scale production and antiviral efficacy of multi-target double-stranded RNA for the prevention of white spot syndrome virus (WSSV) in shrimp.Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.Expression, purification and characterization of a recombinant fusion protein based on the human papillomavirus-16 E7 antigenPhase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.DNA vaccine manufacture: scale and quality.Vaccination with a piggyBac plasmid with transgene integration potential leads to sustained antigen expression and CD8(+) T cell responsesThe Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies.Rational engineering of Escherichia coli strains for plasmid biopharmaceutical manufacturing.Strategies and hurdles using DNA vaccines to fish.Towards effective non-viral gene delivery vector.Modulating APOBEC expression enhances DNA vaccine immunogenicity.Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers.Plasmid DNA fermentation strain and process-specific effects on vector yield, quality, and transgene expression.DNA Vaccines Against Maedi-Visna Virus.Modification of glucose import capacity in Escherichia coli: physiologic consequences and utility for improving DNA vaccine productionEngineering Escherichia coli to increase plasmid DNA production in high cell-density cultivations in batch mode.Effect of plasmid replication deregulation via inc mutations on E. coli proteome & simple flux model analysis.Persistence of an Oncogenic Papillomavirus Genome Requires cis Elements from the Viral Transcriptional Enhancer.DNA vaccines for fish: Review and perspectives on correlates of protection.Testing plasmid stability of Escherichia coli using the Continuously Operated Shaken BIOreactor System.Enhanced protection against nasopharyngeal carriage of Streptococcus pneumoniae elicited by oral multiantigen DNA vaccines delivered in attenuated Salmonella typhimurium.Live Bacterial Vectors-A Promising DNA Vaccine Delivery System.The influence of nonconjugative Escherichia coli plasmids on biofilm formation and resistance.De novo creation of MG1655-derived E. coli strains specifically designed for plasmid DNA production.The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene Delivery in Human Cells.Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Tipping the Proteome with Gene-Based Vaccines: Weighing in on the Role of Nanomaterials
P2860
Q30528837-911EE682-E8A4-44EB-B838-D5319D2F6F57Q30841376-82A3092C-DB90-454F-97B1-2758404EFB33Q33759465-D30DC27A-1DC2-4966-A09C-ECD3BA8AD5A4Q33826187-B6E80CDB-8E4A-4261-B16B-D73F968ED2F1Q34222163-49177D5C-0DC0-4840-A181-1D56D4778FA9Q34316015-09203089-7872-41AF-B7BF-EB4633B8F4CBQ34471220-87C4942D-FED2-4626-9306-BAD73221B9A5Q34487821-0BCB1FEF-8676-4650-8DE9-080A9B345EAEQ34706913-622523F9-DD52-4C9A-9FB7-DB9806CF6D0EQ35187132-AACA55B3-CE05-4956-BEAB-78091BA9DA14Q35802958-1937F2EA-931D-42DC-A24C-3FF491C51EC9Q35826665-772F4F5F-6B81-4C86-97C9-D1CA3127B1F7Q35857534-6AA390B6-6A15-4AC0-AAC9-E3B2F42EDEA3Q36249053-1C731728-25CA-4175-9B3C-81BB477F6BC9Q36662802-479F6E5B-1A20-49E9-9A30-526C02FFFE35Q36690209-01571231-330E-49D1-B1FA-8173C36B6C64Q37590348-7306F907-C2C0-427F-976C-C57D43FB4B32Q37680063-256586D3-CA55-40CC-9B1A-7591F9C89CCAQ37729321-76C05E0E-C0AF-41D8-820A-2982867B5A48Q37793082-27AB02EF-3167-414F-8E77-0D2355BC4C8AQ37931183-ECB76AC9-3202-48CF-96AE-9C2E84A65D15Q38189450-ED4F6509-C1AD-493B-AF45-502B236ED223Q38830057-C8284BEE-C614-4E2E-97A2-D2DB6C56A4A9Q38870396-1471E61C-33D3-4249-93D4-513DF40FEBBFQ39627661-9495483F-41FA-4374-A81A-5570346D9220Q39839158-58F65808-69A3-4E8E-9446-396806FA78C2Q40715606-20ACD0C5-1518-4925-B8CD-79A6FECC3B84Q40740203-F6673EEE-A660-4E7B-8ADB-2D8694771C9AQ41699306-FBAAA59F-2F2E-4149-9796-44065AB369DFQ43184002-2F2E3A9E-3FFC-4AAE-85CD-1FBC63887897Q45852293-8346C6D6-FAD2-4513-963F-5B89E81640DAQ47602484-F0A2B214-2A56-4407-AAF1-D92D0170476FQ47695624-9118785B-535E-4AB5-B70B-0242EB926C68Q50048224-07C6D6A1-E182-479C-86C5-4782E91A610AQ52640510-812A8A79-F1CF-4EDE-90B4-4F6F9475CF80Q53099285-F3C7439A-EB50-4B79-B10C-A7E511859542Q54330466-8E3D9D40-BEB4-4D87-A5EA-C29D55B2365AQ55365935-90ECD9FE-4ADF-42F9-805C-D72104594ECBQ55432126-A0E94C4B-3464-4FC0-A5A6-4ADF936C08B5Q58910709-83F1F76D-4DE0-4622-9082-42C531886511
P2860
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@en
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@nl
type
label
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@en
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@nl
prefLabel
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@en
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@nl
P2093
P2860
P1476
Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.
@en
P2093
Aaron E Carnes
Clague P Hodgson
James A Williams
P2860
P304
P356
10.1016/J.BIOTECHADV.2009.02.003
P577
2009-02-20T00:00:00Z